Optegra first to use cataract laser in UK

Article

Optegra is the first to offer the LensAR cataract laser in its London eye hospital.

Optegra is the first to offer the LensAR cataract laser in its London eye hospital.

The LensAR system, launched by Topcon, will be operated by a team of consultant ophthalmic surgeons led by Director of Laser Cataract Surgery for Optegra, Sundeep Kheterpal.

CE-marked and user-friendly, the system has a servo-controlled docking system that features a 'no corneal touch' liquid patient interface. This reportedly improves patient comfort and avoids compression and distortion to the cornea.

Mr Kheterpal commented, "Optegra has invested in this latest equipment to ensure we continue to offer the best possible service to our patients. Suitable for treatment of patients having both cataract surgery and Clarivu permanent lens replacement, the LensAR system has been designed to enhance the accuracy of surgery."

"The advantages of LensAR include full 3D custom imaging (CSI) of each individual eye, both posterior and anterior, to ensure precision and reproducibility. This enables the laser technology to perform laser incisions, which are more consistent and precise than ever before. The imaging is fully automated and there are multiple screens for ultimate accuracy and detail, leading to a most highly-informed diagnosis and accurate surgical procedure."

Optometrists and physicians wishing to offer their patients this cataract laser treatment are welcome to contact Hospital Manager Farzam Jafari, Optegra Eye Hospital, London, on +44 800 358 0825.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.